About Horizon Pharma (NASDAQ:HZNP)
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Debt
Debt-to-Equity Ratio1.91%
Current Ratio1.63%
Quick Ratio1.54%
Price-To-Earnings
Trailing P/E Ratio11.62
Forward P/E Ratio9.59
P/E Growth0.58
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales2.14
Cash Flow$3.0467 per share
Price / Cash4.50
Book Value$6.05 per share
Price / Book2.27
Profitability
EPS (Most Recent Fiscal Year)$1.18
Net Income$-410,520,000.00
Net Margins-38.87%
Return on Equity18.44%
Return on Assets4.62%
Miscellaneous
Employees1,010
Outstanding Shares164,980,000
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma declared that its board has approved a share buyback program on Sunday, June 4th 2017, which authorizes the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.22 by $0.07. The biopharmaceutical company had revenue of $274.22 million for the quarter, compared to analysts' expectations of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. Horizon Pharma's revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 earnings per share. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What price target have analysts set for HZNP?
11 brokerages have issued 1-year price objectives for Horizon Pharma's shares. Their predictions range from $13.00 to $24.00. On average, they anticipate Horizon Pharma's share price to reach $18.6364 in the next year. View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Cantor Fitzgerald analysts commented, "Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral." (3/14/2018)
- 2. According to Zacks Investment Research, "Horizon has been focused on expanding its orphan drug business.The company has been quite active on the acquisition front over the past few quarters. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (10/10/2017)
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD) and Supernus Pharmaceuticals (SUPN).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & Chief Exec. Officer (Age 51)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 53)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 64)
- Mr. Robert F. Carey, Chief Bus. Officer & Exec. VP (Age 59)
- Mr. Miles W. McHugh, Chief Accounting Officer and Sr. VP (Age 53)
Has Horizon Pharma been receiving favorable news coverage?
Media coverage about HZNP stock has trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Pharma earned a news impact score of 0.06 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $13.71.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $2.26 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Horizon Pharma (NASDAQ:HZNP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Horizon Pharma in the last 12 months. Their average twelve-month price target is $18.6364, suggesting that the stock has a possible upside of 35.93%. The high price target for HZNP is $24.00 and the low price target for HZNP is $13.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.91 | 2.91 | 2.92 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.6364 | $18.6364 | $19.25 | $18.00 |
| Price Target Upside: | 35.93% upside | 21.73% upside | 27.57% upside | 27.75% upside |
Horizon Pharma (NASDAQ:HZNP) Consensus Price Target History
Horizon Pharma (NASDAQ:HZNP) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Horizon Pharma (NASDAQ:HZNP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Horizon Pharma (NASDAQ HZNP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 86.55%
Horizon Pharma (NASDAQ HZNP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2017 | Michael G Grey | Director | Buy | 10,000 | $9.48 | $94,800.00 | |  |
| 3/1/2017 | Robert Carey | EVP | Sell | 31,808 | $16.03 | $509,882.24 | | |
| 8/2/2016 | Jeffrey W. Sherman | EVP | Sell | 2,900 | $20.00 | $58,000.00 | | |
| 6/15/2016 | Virinder Nohria | Director | Sell | 25,000 | $17.69 | $442,250.00 | 189,836 | |
| 2/26/2016 | Jeffrey W Sherman | EVP | Sell | 4,100 | $20.00 | $82,000.00 | 149,648 | |
| 12/10/2015 | Jeffrey W Sherman | EVP | Sell | 4,456 | $20.00 | $89,120.00 | 105,132 | |
| 9/21/2015 | Jeffrey W Sherman | EVP | Sell | 7,750 | $31.78 | $246,295.00 | 105,132 | |
| 7/15/2015 | Jeffrey W Sherman | EVP | Sell | 26,887 | $35.55 | $955,832.85 | | |
| 3/13/2015 | Jeff Himawan | Director | Sell | 554,564 | $22.44 | $12,444,416.16 | | |
| 3/10/2015 | Jeff Himawan | Director | Sell | 1,614,827 | $21.85 | $35,283,969.95 | | |
| 11/19/2014 | Jeff Himawan | Director | Sell | 3,450,000 | $12.05 | $41,572,500.00 | | |
| 11/19/2014 | Jeffrey W Sherman | EVP | Sell | 24,999 | $12.05 | $301,237.95 | | |
| 11/19/2014 | Timothy P Walbert | CEO | Sell | 150,000 | $12.05 | $1,807,500.00 | | |
| 11/13/2014 | Balaji Venkataraman | Major Shareholder | Sell | 6,086,957 | $11.54 | $70,243,483.78 | | |
| 11/13/2014 | Virinder Nohria | Director | Sell | 1,739,130 | $11.54 | $20,069,560.20 | | |
| 9/30/2014 | Vaere Robert J De | CFO | Sell | 51,942 | $12.28 | $637,847.76 | | |
| 5/19/2014 | Timothy Walbert | CEO | Sell | 31,742 | $12.94 | $410,741.48 | 148,930 | |
| 5/19/2014 | Todd Smith | EVP | Sell | 10,159 | $12.94 | $131,457.46 | 44,552 | |
| 5/19/2014 | Vaere Robert De | CFO | Sell | 12,939 | $12.94 | $167,430.66 | 88,555 | |
| 12/13/2013 | Jeffrey Bird | Director | Buy | 668,673 | $6.50 | $4,346,374.50 | 5,000 | |
| 12/9/2013 | Timothy Walbert | CEO | Sell | 12,124 | $6.79 | $82,321.96 | 148,497 | |
| 12/9/2013 | Todd Smith | EVP | Sell | 11,322 | $6.91 | $78,235.02 | 40,961 | |
| 11/21/2013 | Jeffrey Bird | Director | Buy | 151,089 | $6.24 | $942,795.36 | 5,000 | |
| 9/25/2012 | Jeffrey W Bird | Director | Buy | 575,356 | $3.49 | $2,007,992.44 | | |
(Data available from 1/1/2013 forward)
Horizon Pharma (NASDAQ HZNP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public
finance.yahoo.com - April 18 at 8:14 AM |
 | Zacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $245.18 Million
www.americanbankingnews.com - April 18 at 1:50 AM |
| Zacks: Analysts Expect Horizon Pharma PLC (HZNP) to Post $0.11 EPS
www.americanbankingnews.com - April 16 at 11:10 PM |
| Cantor Fitzgerald Analysts Give Horizon Pharma (HZNP) a $17.00 Price Target
www.americanbankingnews.com - April 16 at 7:39 AM |
| Cantor Fitzgerald Analysts Give Horizon Pharma (HZNP) a $13.00 Price Target
www.americanbankingnews.com - April 15 at 9:31 AM |
| Horizon Pharma (HZNP) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 14 at 10:53 PM |
| Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
finance.yahoo.com - April 12 at 5:40 PM |
| Horizon Pharma (HZNP) Receives "Neutral" Rating from Mizuho
www.americanbankingnews.com - April 11 at 11:52 PM |
| Horizon Pharma (HZNP) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - April 11 at 5:35 PM |
| New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - April 11 at 8:28 AM |
| Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
finance.yahoo.com - April 9 at 8:16 AM |
| Horizon Pharma (HZNP) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 4:58 PM |
| Piper Jaffray Analysts Give Horizon Pharma (HZNP) a $18.00 Price Target
www.americanbankingnews.com - April 7 at 12:30 PM |
 | These New Pharma Bros Are Wreaking Havoc on Prescription Drug Prices
www.bloomberg.com - April 7 at 8:21 AM |
| BidaskClub Downgrades Horizon Pharma (HZNP) to Sell
www.americanbankingnews.com - April 7 at 7:02 AM |
 | Commit To Buy Horizon Pharma At $10, Earn 11% Using Options
www.nasdaq.com - April 6 at 5:43 PM |
| When These New Pharma Bros Show Up, Drug Prices Tend to Go Monumentally Higher
finance.yahoo.com - April 6 at 8:24 AM |
| Horizon Pharma PLC (HZNP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 11:41 AM |
 | This Morning's Technical Outlook on Generic Drugs Stocks -- Lipocine, Akorn, Collegium Pharma, and Horizon Pharma
www.prnewswire.com - April 4 at 8:19 AM |
| Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease
finance.yahoo.com - April 2 at 5:29 PM |
| Horizon Pharma (HZNP) Down 3.9% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 2 at 8:36 AM |
| $245.18 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter
www.americanbankingnews.com - April 2 at 5:33 AM |
| Horizon Pharma (HZNP) PT Raised to $21.00
www.americanbankingnews.com - April 1 at 3:42 PM |
| Zacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - March 31 at 1:18 AM |
| Edited Transcript of HZNP earnings conference call or presentation 28-Feb-18 1:00pm GMT
finance.yahoo.com - March 29 at 5:32 PM |
| Is a Recession in the Cards? 4 Safe Bets for Your Portfolio
finance.yahoo.com - March 29 at 5:32 PM |
| BidaskClub Upgrades Horizon Pharma (HZNP) to Hold
www.americanbankingnews.com - March 28 at 11:26 AM |
| Horizon Pharma (HZNP) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 12:34 AM |
| Horizon Pharma (HZNP) Downgraded by ValuEngine
www.americanbankingnews.com - March 25 at 5:22 PM |
| Horizon Pharma (HZNP) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 23 at 12:30 AM |
| Physicians And Patients Finally Avoiding Horizon's Expensive, Low-Value Pain Drugs Duexis And Vimovo
finance.yahoo.com - March 15 at 6:14 PM |
| Is Horizon Pharma Public (HZNP) a Great Stock for Value Investors Right Now?
finance.yahoo.com - March 15 at 6:14 PM |
| Horizon Pharma (HZNP) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - March 14 at 9:40 PM |
| ValuEngine Lowers Horizon Pharma (HZNP) to Hold
www.americanbankingnews.com - March 13 at 10:19 PM |
| Horizon Pharma PLC (HZNP) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 3:40 PM |
| 5 Cheap Breakout Stocks for Explosive Returns - Nasdaq
www.nasdaq.com - March 9 at 8:17 AM |
| 5 Cheap Breakout Stocks for Explosive Returns
finance.yahoo.com - March 9 at 8:17 AM |
| FY2018 Earnings Forecast for Horizon Pharma PLC (HZNP) Issued By Cantor Fitzgerald
www.americanbankingnews.com - March 7 at 11:51 AM |
| Horizon Pharma PLC (HZNP) Shares Sold by Sei Investments Co.
www.americanbankingnews.com - March 6 at 7:11 AM |
| State of Wisconsin Investment Board Has $2.39 Million Position in Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - March 4 at 9:31 AM |
| Swiss National Bank Purchases 7,800 Shares of Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - March 4 at 8:22 AM |
| Horizon Pharma (HZNP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 3 at 5:52 PM |
| Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View
finance.yahoo.com - March 2 at 6:13 PM |
| Globeflex Capital L P Grows Holdings in Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - March 2 at 4:18 PM |
| Horizon Pharma (HZNP) Price Target Raised to $16.00 at Morgan Stanley
www.americanbankingnews.com - March 2 at 2:02 PM |
| Horizon Pharma Sees Unusually High Options Volume (HZNP)
www.americanbankingnews.com - March 2 at 7:30 AM |
| UBS Group Reiterates $20.00 Price Target for Horizon Pharma (HZNP)
www.americanbankingnews.com - March 1 at 10:58 PM |
| Horizon Pharma's (HZNP) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - March 1 at 8:46 PM |
| Horizon Pharma's (HZNP) Buy Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - March 1 at 8:13 PM |
| Schwab Charles Investment Management Inc. Boosts Position in Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - March 1 at 5:14 PM |
Horizon Pharma (NASDAQ:HZNP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Horizon Pharma (NASDAQ:HZNP) Income Statement, Balance Sheet and Cash Flow Statement
Horizon Pharma (NASDAQ HZNP) Stock Chart for Sunday, April, 22, 2018
Loading chart…
